ESSENCE: semaglutide improved liver histology in fatty liver with inflammation

Phase 3 in 1,197 people with metabolic steatohepatitis and moderate or advanced fibrosis confirmed by biopsy.

ESSENCE is a phase 3, double-blind trial in people with metabolic dysfunction-associated steatohepatitis (MASH) and stage 2 or 3 fibrosis confirmed by biopsy. They were assigned 2:1 to weekly semaglutide or placebo.

Both primary endpoints — resolution of steatohepatitis without worsening fibrosis, and improvement in fibrosis without worsening steatohepatitis — favoured semaglutide. Later analyses saw improvements across all levels of weight loss.

In three points

Phase 3 trial with 1,197 participants and liver biopsy
Liver inflammation and fibrosis improved
Improvements appeared across different degrees of weight loss

Compounds mentioned

Semaglutide

Original source: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
New England Journal of Medicine

Plain-language summary by SYNTRA LABS based on the original publication and checked against its source. It is not medical advice or a recommendation for use. SYNTRA LABS compounds are for research use only and not for human consumption.